Fred Hutch spinout Nohla Therapeutics raises $43.5M Series A led by Arch to advance cord‑blood leukemia therapies

Nohla Therapeutics, a Fred Hutch spinout, raised $43.5 million in a Series A led by Arch Venture Partners to advance cord‑blood transplant therapies for high‑risk leukemia, funding two lead candidates including Phase 2 NLA-101 and a second program slated for trials in 2018.

No comments yet.